Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of glasdegib for R/R AML

Andrius Žučenka • 10 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Cytarabine Glasdegib

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the safety and efficacy of glasdegib for relapsed/refractory (R/R) acute myeloid leukemia (AML). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Andrius Žučenka

2:18
VEN-AZA versus intensive chemotherapy as bridging therapy in patients with MDS
Andrius Žučenka • 8 Dec 2023
3:52
Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka • 8 Dec 2023
2:27
Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka • 8 Dec 2023
2:12
Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
Andrius Žučenka • 8 Dec 2023

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals